Cover Image
市場調查報告書

Adienne Pharma & Biotech的產品平台分析

Adienne Pharma & Biotech - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 293949
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Adienne Pharma & Biotech的產品平台分析 Adienne Pharma & Biotech - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 20 Pages
簡介

Adienne Pharma & Biotech是總公司設立於義大利的生物製藥企業。正在開發及商品化用於同類造血細胞及自體血液前驅細胞的移植前治療之TEPADINA等針對罕見疾病,自體免疫疾病,造血幹細胞移植,器官移植等領域的專門產品。

本報告提供Adienne Pharma & Biotech 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Adienne Pharma & Biotech 基本資料

  • Adienne Pharma & Biotech 概要
  • 主要資訊
  • 企業資料

Adienne Pharma & Biotech :R&D概要

  • 主要的治療範圍

Adienne Pharma & Biotech :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Adienne Pharma & Biotech :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Adienne Pharma & Biotech :藥物簡介

  • begelomab
  • Ergidina
  • Mubodina

Adienne Pharma & Biotech :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Adienne Pharma & Biotech :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06619CDB

Summary

Global Markets Direct's, 'Adienne Pharma & Biotech - Product Pipeline Review - 2014', provides an overview of the Adienne Pharma & Biotech's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Adienne Pharma & Biotech's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Adienne Pharma & Biotech including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Adienne Pharma & Biotech's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Adienne Pharma & Biotech's pipeline products

Reasons to buy

  • Evaluate Adienne Pharma & Biotech's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Adienne Pharma & Biotech in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Adienne Pharma & Biotech's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Adienne Pharma & Biotech and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Adienne Pharma & Biotech
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Adienne Pharma & Biotech and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Adienne Pharma & Biotech Snapshot
    • Adienne Pharma & Biotech Overview
    • Key Information
    • Key Facts
  • Adienne Pharma & Biotech - Research and Development Overview
    • Key Therapeutic Areas
  • Adienne Pharma & Biotech - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Adienne Pharma & Biotech - Pipeline Products Glance
    • Adienne Pharma & Biotech - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Adienne Pharma & Biotech - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Adienne Pharma & Biotech - Drug Profiles
    • begelomab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ergidina
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Mubodina
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Adienne Pharma & Biotech - Pipeline Analysis
    • Adienne Pharma & Biotech - Pipeline Products by Target
    • Adienne Pharma & Biotech - Pipeline Products by Route of Administration
    • Adienne Pharma & Biotech - Pipeline Products by Molecule Type
    • Adienne Pharma & Biotech - Pipeline Products by Mechanism of Action
  • Adienne Pharma & Biotech - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Adienne Pharma & Biotech, Key Information
  • Adienne Pharma & Biotech, Key Facts
  • Adienne Pharma & Biotech - Pipeline by Indication, 2014
  • Adienne Pharma & Biotech - Pipeline by Stage of Development, 2014
  • Adienne Pharma & Biotech - Monotherapy Products in Pipeline, 2014
  • Adienne Pharma & Biotech - Phase II, 2014
  • Adienne Pharma & Biotech - Preclinical, 2014
  • Adienne Pharma & Biotech - Pipeline by Target, 2014
  • Adienne Pharma & Biotech - Pipeline by Route of Administration, 2014
  • Adienne Pharma & Biotech - Pipeline by Molecule Type, 2014
  • Adienne Pharma & Biotech - Pipeline Products by Mechanism of Action, 2014
  • Adienne Pharma & Biotech, Subsidiaries

List of Figures

  • Adienne Pharma & Biotech - Pipeline by Top 10 Indication, 2014
  • Adienne Pharma & Biotech - Pipeline by Stage of Development, 2014
  • Adienne Pharma & Biotech - Monotherapy Products in Pipeline, 2014
  • Adienne Pharma & Biotech - Pipeline by Top 10 Target, 2014
  • Adienne Pharma & Biotech - Pipeline by Top 10 Molecule Type, 2014
  • Adienne Pharma & Biotech - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top